Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Amneal Pharmaceuticals's total assets was $3.78B at Jun 30, 2026. For fiscal 2025 it was $3.68B, up 5.1% from the year before. The highest annual figure on record is $4.35B in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.68B | +5.1% |
| FY2024 | Dec 31, 2024 | $3.50B | +0.8% |
| FY2023 | Dec 31, 2023 | $3.47B | -8.6% |
| FY2022 | Dec 31, 2022 | $3.80B | -3.6% |
| FY2021 | Dec 31, 2021 | $3.94B | -1.7% |
| FY2020 | Dec 31, 2020 | $4.01B | +9.3% |
| FY2019 | Dec 31, 2019 | $3.67B | -15.8% |
| FY2018 | Dec 31, 2018 | $4.35B | +224.4% |
| FY2017 | Dec 31, 2017 | $1.34B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.78B | +10.3% |
| Q1 FY2026 | Mar 31, 2026 | $3.54B | +5.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.68B | +5.1% |
| Q3 FY2025 | Sep 30, 2025 | $3.60B | +4.0% |
| Q2 FY2025 | Jun 30, 2025 | $3.42B | -2.5% |
| Q1 FY2025 | Mar 31, 2025 | $3.37B | -2.6% |
| Q4 FY2024 | Dec 31, 2024 | $3.50B | +0.8% |
| Q3 FY2024 | Sep 30, 2024 | $3.46B | -6.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.51B | -5.2% |
| Q1 FY2024 | Mar 31, 2024 | $3.46B | -4.7% |
| Q4 FY2023 | Dec 31, 2023 | $3.47B | -8.6% |
| Q3 FY2023 | Sep 30, 2023 | $3.69B | -4.8% |
| Q2 FY2023 | Jun 30, 2023 | $3.70B | -8.4% |
| Q1 FY2023 | Mar 31, 2023 | $3.63B | -6.7% |
| Q4 FY2022 | Dec 31, 2022 | $3.80B | -3.6% |
| Q3 FY2022 | Sep 30, 2022 | $3.87B | -2.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.04B | +0.5% |
| Q1 FY2022 | Mar 31, 2022 | $3.89B | -1.8% |
| Q4 FY2021 | Dec 31, 2021 | $3.94B | -1.7% |
| Q3 FY2021 | Sep 30, 2021 | $3.97B | -1.6% |
| Q2 FY2021 | Jun 30, 2021 | $4.02B | -0.8% |
| Q1 FY2021 | Mar 31, 2021 | $3.96B | -9.8% |
| Q4 FY2020 | Dec 31, 2020 | $4.01B | +9.3% |
| Q3 FY2020 | Sep 30, 2020 | $4.04B | +9.0% |
| Q2 FY2020 | Jun 30, 2020 | $4.06B | -4.8% |
| Q1 FY2020 | Mar 31, 2020 | $4.39B | +0.1% |
| Q4 FY2019 | Dec 31, 2019 | $3.67B | -15.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.70B | -19.2% |
| Q2 FY2019 | Jun 30, 2019 | $4.26B | -6.2% |
| Q1 FY2019 | Mar 31, 2019 | $4.38B | – |
| Q4 FY2018 | Dec 31, 2018 | $4.35B | +224.4% |
| Q3 FY2018 | Sep 30, 2018 | $4.58B | – |
| Q2 FY2018 | Jun 30, 2018 | $4.54B | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $1.34B | – |
See a number that looks wrong?